# U.S. Child Cannabis Exposures Through 2024: What the New Poison Center Study Shows > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/us-child-cannabis-exposures-through-2024-poison-center-study-post/ > **Published:** 2026-10-02T09:20:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-17T15:55:01-04:00 > **Clinical Summary:** A national study tracks US child cannabis exposures from 2000 to 2024. Dr. Caplan reviews the poison center data and what it means for parent safety. --- CED Clinical Relevance #82 High [Public Health](https://cedclinic.com/hopkinton-synthetic-cannabinoid-kratom-ban/) Relevance A fresh national poison-center surveillance paper shows a large pediatric safety signal with clear counseling and prevention relevance, even though the design remains descriptive rather than causal. Clinical Insight | CED Clinic This June 26, 2026 Journal of Addiction Medicine paper is not a treatment-efficacy study. It is a national pediatric safety signal built from America’s Poison Centers data across 2000 through 2024, and that makes it clinically useful for a different reason. Parents, pediatricians, emergency clinicians, and cannabis clinicians all need a realistic picture of how often cannabis exposures are being reported in children, which age groups are rising, and what the study design can and cannot prove about policy or product drivers. The paper earns attention because the reported increases are large and recent. It also requires restraint because descriptive surveillance should sharpen prevention and counseling without being oversold as a single-cause explanation. PediatricsSafety SignalPoison CentersPublic HealthCannabis AudienceParents, caregivers, pediatric clinicians, emergency clinicians, and cannabis-science readers Primary Topicreported [pediatric cannabis](https://cedclinic.com/cannabis-for-childrens-behavior/) exposures in U.S. children age 12 and under Source[Read the full study](https://journals.lww.com/journaladdictionmedicine/fulltext/9900/changes_in_exposures_of_us_children_ages_12_and.734.aspx) Table of Contents - [U.S. Child Cannabis Exposures Through 2024: What the New Poison Center Study Shows](#US_Child_Cannabis_Exposures_Through_2024_What_the_New_Poison_Center_Study_Shows)[How to Read a Pediatric Cannabis Safety Signal Without Overstating It](#How_to_Read_a_Pediatric_Cannabis_Safety_Signal_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[A Real Household Safety Signal](#A_Real_Household_Safety_Signal) - [Useful for Counseling and Triage Awareness](#Useful_for_Counseling_and_Triage_Awareness) - [Large Trends Still Need Causal Humility](#Large_Trends_Still_Need_Causal_Humility) - [Young Children Carry the Sharpest Prevention Burden](#Young_Children_Carry_the_Sharpest_Prevention_Burden) - [Trend Surveillance Can Justify Prevention Pressure](#Trend_Surveillance_Can_Justify_Prevention_Pressure) - [Storage and Packaging Matter Most at Bedside Level](#Storage_and_Packaging_Matter_Most_at_Bedside_Level) - [What Better Follow-Up Should Clarify](#What_Better_Follow-Up_Should_Clarify) - [Good Policy Reading Requires Narrow Claims](#Good_Policy_Reading_Requires_Narrow_Claims) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # U.S. Child Cannabis Exposures Through 2024: What the New Poison Center Study Shows A June 26, 2026 Journal of Addiction Medicine study found that cannabis exposures reported to U.S. poison centers rose sharply in children age 12 and under from 2009 through 2024. The signal is clinically important for prevention and counseling, but the study is descriptive and does not prove a one-cause policy story. What This Study Teaches Us The paper teaches that pediatric cannabis exposures reported to America’s Poison Centers increased dramatically after 2009 in both children under 6 and children age 6 to 12, making this a meaningful public-health and counseling signal. It also teaches that surveillance data are best used to identify risk patterns and prevention priorities, not to make overly simple causal claims. Why This Matters Families and clinicians often hear about accidental cannabis ingestions as isolated headlines. This paper matters because it puts those events into a national trend frame and shows that the signal is not trivial or static. That is useful for prevention counseling, safer storage conversations, pediatric triage awareness, and public-health messaging that stays grounded in evidence rather than panic or minimization. Study SnapshotStudy TypeRetrospective descriptive time-trend analysisData SourceAmerica’s Poison Centers / National Poison Data SystemPopulationU.S. children age 12 and under with reported cannabis exposuresTime Window2000 through 2024Main Pediatric TrendUnder-6 reported exposures rose from 132 in 2009 to 8,430 in 2024Older Child TrendAges 6 to 12 rose from 21 in 2009 to 2,894 in 2024Reported Percent Change6,386% under age 6 and 13,781% in ages 6 to 12 from 2009 to 2024JournalJournal of Addiction MedicinePrimary Publication DateJune 26, 2026PMID42359703DOI10.1097/ADM.0000000000001720Key LimitationDescriptive surveillance can show timing and scale, but not simple causation for every increase Clinical Bottom Line This paper supports stronger pediatric prevention and counseling conversations because reported cannabis exposures in U.S. children rose sharply through 2024. It should be read as a large public-health warning signal, not as proof that one law, one product type, or one explanation accounts for the whole increase. What the Study Actually Measured The authors performed a retrospective descriptive analysis of annual pediatric cannabis exposure cases reported to America’s Poison Centers and entered into the National Poison Data System from 2000 through 2024. That matters because poison center surveillance is not the same as a [randomized trial](https://cedclinic.com/cannabidiol-effects-on-appetite/) or even a patient-level cohort. It is best at identifying scale, timing, and direction of a public-health signal rather than proving why every reported exposure happened. What the Numbers Show According to the abstract, reported exposures among children under 6 were stable from 2000 to 2009, then climbed from 132 in 2009 to 8,430 in 2024. In children age 6 to 12, reported exposures rose from 21 to 2,894 over the same period. Those are not subtle changes. Even though poison center reports are not identical to total true exposures, the magnitude of increase is large enough to make this a serious pediatric counseling and prevention issue. Why This Does Not Prove a One-Cause Policy Story The authors describe the rise as temporally associated with federal [cannabis policy](https://cedclinic.com/medical-cannabis-schedule-iii-order/) changes in 2009, 2013, and 2018. That wording matters. Temporal association can be important without proving that policy alone caused the entire increase. Changes in product availability, product form, household storage, reporting behavior, awareness, packaging, and market evolution can all shape surveillance trends. A careful reading keeps those possibilities open instead of collapsing the paper into a single political claim. How Families and Clinicians Can Use This Safely The practical use of this paper is prevention: safer storage, child-resistant packaging, direct household counseling, and earlier suspicion of accidental ingestion when a child presents with unexplained neurologic or sedating symptoms. The practical use is not to assume that every cannabis product carries the same pediatric risk profile or that a surveillance paper settles every policy debate. It is strongest when used to improve vigilance and prevention behavior. How Strong Is This Evidence? This is meaningful public-health evidence because it uses a large national poison-center dataset across many years and addresses a clinically important pediatric risk. It is still surveillance evidence, which means it is strongest on trend detection and weaker on causal attribution, product-specific conclusions, and patient-level prediction. Where This Paper Deserves Skepticism The right skepticism is methodological, not dismissive. Poison center reports can be influenced by awareness, reporting behavior, and coding practices, and the abstract alone does not establish which formulations or household circumstances drove the increase. Those limits do not erase the signal, but they do narrow the claim. What This Paper Does Not Show This paper does not show that one policy change explains every pediatric exposure, that all cannabis products are equally responsible, that poison center cases capture every true exposure, or that the study can predict risk for one individual child or household. How This Fits With the Broader Clinical Conversation Pediatric [cannabis safety](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) conversations often swing between minimization and alarm. Surveillance papers like this help anchor the conversation in observed national reporting trends rather than anecdotes alone. CED readers have also seen that pediatric risk does not depend only on one molecule. Packaging, household storage, edible appeal, labeling, and caregiver awareness can all influence whether a child gets exposed and whether an exposure is recognized quickly. That broader context is why a public-health paper can be worth a standalone report even though it is not a treatment paper. Prevention evidence is still clinical evidence when it changes how families and clinicians should prepare. Dr. Caplan’s Take *I read this as a prevention paper first. The important question is not whether the trend line is politically convenient, but whether families and clinicians treat it as a real pediatric safety warning.* *The scale of increase is hard to ignore, and the design still deserves discipline. We can take the signal seriously without pretending the study proves more than surveillance can prove.* What a Careful Reader Should Take Away A careful reader should leave with two ideas at once: pediatric cannabis exposures reported to poison centers rose sharply through 2024, and the safest way to use that finding is to strengthen prevention, counseling, and storage practices without overstating causation. Evidence Interpretation Guide ## How to Read a Pediatric Cannabis Safety Signal Without Overstating It Safety papers do not have to be randomized to matter clinically, but they do have to be read for the kind of claim they actually support. This study is strongest when it is used to understand trend direction, scale, and prevention urgency. ### A Four-Step Reading Frame **Start with the dataset**Recognize that this paper uses poison-center surveillance, which is built for signal detection rather than precise causal proof. **Check the age groups**The paper separates younger children from older children, which helps show that the rise is not limited to a single narrow pediatric subgroup. **Watch the wording around policy**Temporal association is meaningful, but it should not be silently upgraded into a one-cause explanation. **Translate into prevention**The safest clinical use is better storage, counseling, packaging awareness, and earlier recognition of accidental ingestion. The Research Question What happened to reported cannabis exposures in U.S. children age 12 and under from 2000 through 2024? The Family Question What should parents, caregivers, and clinicians do differently if pediatric exposure reports are rising this sharply? The Bottom Line The evidence supports stronger prevention and awareness more than it supports simple causal rhetoric. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens OverviewThe same pediatric surveillance study can be read as a family-safety warning, an emergency-medicine signal, a public-health trend report, or a policy argument. The most defensible reading keeps those layers separate. #### A Real Household Safety Signal Families should read this as a reminder that cannabis products are not neutral household items when children are present. The study does not need to prove every cause before it becomes relevant to home storage and supervision. The practical takeaway is not fear for its own sake. It is better prevention, earlier recognition of accidental ingestion, and clearer conversations with anyone who stores cannabis where children live or visit. Lens takeawayTreat cannabis storage like pediatric safety equipment, not like an afterthought. #### Useful for Counseling and Triage Awareness Clinicians can use this paper to justify more explicit counseling around storage, edible appeal, and pediatric exposure history. It also supports keeping cannabis ingestion on the differential when a child presents with unexplained sedation or neurologic change. Its main clinical value is not prescribing. It is risk recognition, prevention messaging, and sharper suspicion in emergency and pediatric settings. Lens takeawayUse the paper to improve counseling and recognition, not to make product-specific claims it did not test. #### Large Trends Still Need Causal Humility A skeptical reader should resist turning a descriptive trend paper into a one-variable explanation. Reporting systems change, awareness changes, and markets change, all of which can influence counts. That skepticism is healthy, but it should not erase the magnitude of the rise. The more disciplined conclusion is that the signal is real and the mechanism mix still needs better study. Lens takeawayThe study is strong on trend direction and weak on single-cause certainty. #### Young Children Carry the Sharpest Prevention Burden Children under 6 are especially important here because exploratory ingestion, attractive product forms, and caregiver unawareness can converge quickly in that age group. The paper supports pediatric counseling that is concrete and repetitive: locked storage, out-of-sight placement, product separation from candy or snacks, and fast action when exposure is suspected. Lens takeawayPediatric prevention works best when counseling is direct, specific, and repeated. #### Trend Surveillance Can Justify Prevention Pressure Public-health readers should see this as a justification for better packaging standards, surveillance refinement, and household education rather than as a complete policy map. The signal is large enough to support intervention discussions even if the exact contribution of each legal or market shift remains unsettled. Lens takeawayPrevention can be justified before every causal detail is solved. #### Storage and Packaging Matter Most at Bedside Level The best bedside translation is practical: ask what products are in the home, where they are stored, whether they resemble candy, and who might access them. For cannabis clinicians, the paper is a reminder that patient education should include household safety, not just adult symptom goals or dosing discussions. Lens takeawayHousehold workflow is often more actionable than abstract policy debate. #### What Better Follow-Up Should Clarify Future work should separate product categories more clearly, link exposures to clinical severity when possible, and distinguish reporting changes from true exposure incidence more precisely. Those next steps would make future pediatric safety counseling even sharper by showing which products, settings, and protections matter most. Lens takeawayThe next upgrade is more granular exposure and severity data, not louder rhetoric. #### Good Policy Reading Requires Narrow Claims This paper will inevitably be used in policy conversations, but the safest policy reading is still a narrow one: reported pediatric exposures rose sharply and public-health safeguards deserve attention. A narrow claim is more credible than a sweeping one. That is especially true in cannabis policy, where overstated causal claims tend to weaken trust even when the underlying safety signal is genuine. Lens takeawayThe strongest policy use is honest about both urgency and design limits. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=U.S.+Child+Cannabis+Exposures+Through+2024%3A+What+the+New+Poison+Center+Study+Shows&url=https%3A%2F%2Fcedclinic.com%2Fus-child-cannabis-exposures-through-2024-poison-center-study%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fus-child-cannabis-exposures-through-2024-poison-center-study%2F) [BlueSky](https://bsky.app/intent/compose?text=U.S.+Child+Cannabis+Exposures+Through+2024%3A+What+the+New+Poison+Center+Study+Shows%20https%3A%2F%2Fcedclinic.com%2Fus-child-cannabis-exposures-through-2024-poison-center-study%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Changes in Exposures of US Children Ages 12 and Under to Cannabis from 2000 to 2024](https://journals.lww.com/journaladdictionmedicine/fulltext/9900/changes_in_exposures_of_us_children_ages_12_and.734.aspx) Related Reading at CED ClinicContinue exploring the evidence[Pediatric Hemp-Derived Cannabinoid and Delta-9-THC Exposures: A National Poison Data Study](https://cedclinic.com/hemp-derived-cannabinoids-pediatric-toxicity-study/) CED coverage of another poison-data paper that helps compare newer pediatric exposure concerns across hemp-derived and delta-9 products. [Compare poison-data findings](https://cedclinic.com/hemp-derived-cannabinoids-pediatric-toxicity-study/)[Cannabis branding may appeal to youth despite regulations, study finds](https://cedclinic.com/cannabis-branding-may-appeal-to-youth-despite-regulations-study-finds/) A related CED piece on how packaging and youth appeal can shape pediatric access risk long before a poison-center call happens. [Read packaging context](https://cedclinic.com/cannabis-branding-may-appeal-to-youth-despite-regulations-study-finds/)[West Haven child hospitalized after eating possible THC gummy, police say](https://cedclinic.com/west-haven-child-hospitalized-after-eating-possible-thc-gummy-police-say/) A local-news clinical context item that shows how accidental ingestion can present in real pediatric cases outside a national dataset. [Read case context](https://cedclinic.com/west-haven-child-hospitalized-after-eating-possible-thc-gummy-police-say/) Similar Studies on CEDClinic.comEarlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [CED Cannabis Science Digest: 3 Withdrawal, Sleep, and Pediatric Exposure Signals](https://cedclinic.com/cannabis-science-digest-june-25-2026-withdrawal-sleep-pediatric-signals/) Three verified cannabis public-health signals on pediatric ingestions, opioid withdrawal self-management, and adolescent sleep-linked use, gathered in one evidence-aware digest. Covers a closely related topic; this CED post is older by about 1 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabis-science-digest-june-25-2026-withdrawal-sleep-pediatric-signals/) Related digest item [In the Mix: 31 More Articles — June 23, 2026](https://cedclinic.com/31-cannabis-articles-clinical-relevance-june-23-2026/) 31 cannabis articles clinical relevance scores fell below the CED threshold in the last 24 hours. This post provides summaries and source links for each article. It offers a clinical relevance review for June 23, 2026. Covers a closely related topic; this CED post is older by about 3 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/31-cannabis-articles-clinical-relevance-june-23-2026/) Related digest item [Cannabis branding may appeal to youth despite regulations, study finds](https://cedclinic.com/cannabis-branding-may-appeal-to-youth-despite-regulations-study-finds/) ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustryPediatricsMental HealthTHC Why This Matters Clinicians should und… Covers a closely related topic; this CED post is older by about 10 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabis-branding-may-appeal-to-youth-despite-regulations-study-finds/) ## Frequently Asked Questions What did this study actually track? It tracked annual cannabis exposure cases in U.S. children age 12 and under that were reported to America's Poison Centers and entered into the National Poison Data System from 2000 through 2024. Did the study prove that legalization caused every increase? No. It is a descriptive time-trend study. It found that pediatric exposure reports rose sharply after 2009 and described that rise as temporally associated with federal policy changes, but it cannot prove that policy alone caused each increase. Which age groups increased the most? Both groups increased markedly. Reported exposures rose from 132 to 8,430 in children under 6 and from 21 to 2,894 in children age 6 to 12 between 2009 and 2024. Why does poison center data matter clinically? Poison center surveillance helps clinicians and public-health teams spot patterns in accidental ingestion and other exposures earlier than waiting for a single hospital or clinic to notice the trend on its own. Does this paper tell us which cannabis products were involved? Not in enough detail to treat one product category as the full explanation. The abstract is strongest on exposure counts and trend direction, not on product-by-product causation. Does this study tell parents exactly how to prevent every exposure? No. It is a surveillance paper, not a household intervention trial. It supports careful storage, packaging, and counseling, but it does not test a specific prevention program. Can this paper be used to judge an individual child's risk? No. It describes national reporting trends, not an individualized probability for one child or one household. Why is the wording around policy kept cautious here? Because descriptive public-health studies can identify strong associations and timing patterns without proving a simple one-cause explanation. Careful wording keeps the evidence aligned with what the design earned. Why is this a standalone CED report instead of a digest item? Because it is a fresh, clinically important pediatric safety signal with a large national dataset, a current publication date, and enough direct patient and public-health relevance to justify a full evidence read. What is the safest bottom-line interpretation? The safest takeaway is that pediatric cannabis exposures reported to poison centers rose sharply through 2024, which strengthens the case for prevention counseling and safer storage without turning a surveillance study into a simple policy proof. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).